In MM with KRAS gene mutations, future directions of targeting the MEK/ERK and PI3K/AKT pathways presents a promising therapeutic approach, and additionally, receptor tyrosine kinase inhibitors, such as those targeting AXL, and immunotherapies like CAR T-cell therapy are being explored to address drug resistance and improve treatment outcomes [13]. The gene discussed is AKT1; the disease is Miyoshi myopathy.